Introduction Boundless Bio is a company that focuses on creating innovative treatments for cancer. Their research is centered around the impact of extra chromosomal DNA (ecDNA) in the development, progression, and reoccurrence of tumors. The company was established by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim and is situated in San Diego, California. |
Disease Domain | Count |
---|---|
Neoplasms | 4 |
Nervous System Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Gene therapy | 2 |
Enzyme | 1 |
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
Kinesin | 1 |
Chk1(Checkpoint kinase 1) | 1 |
Chk1 x DNA | 1 |
Ribonucleotide reductase | 1 |
Target |
Mechanism Chk1 inhibitors [+1] |
Active Org. Boundless Bio, Inc.Startup |
Originator Org. Boundless Bio, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism RNR inhibitors |
Active Org. Boundless Bio, Inc.Startup |
Originator Org. Boundless Bio, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Chk1 inhibitors |
Active Org. Boundless Bio, Inc.Startup |
Originator Org. Boundless Bio, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date28 Mar 2024 |
Sponsor / Collaborator Boundless Bio, Inc.Startup |
Start Date24 Mar 2023 |
Sponsor / Collaborator Boundless Bio, Inc.Startup |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
BBI-355 ( Chk1 x DNA ) | Ovarian Cancer More | Phase 1 |
BBI-825 ( Ribonucleotide reductase ) | Solid tumor More | Phase 1 |
BBI-098 ( Chk1 ) | Glioblastoma More | Preclinical |
ecDTx 3 ( Kinesin ) | Neoplasms More | Discovery |